Emily Bodnar, an analyst from H.C. Wainwright, maintained the Buy rating on Agenus. The associated price target remains the same with $23.00.
Claim 70% Off TipRanks This Holiday Season
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Emily Bodnar’s rating is based on several promising developments in Agenus’s clinical and regulatory landscape. The company has reported encouraging data from its Phase 1b pan-tumor trial, which demonstrated a significant overall survival benefit in patients with various types of cancer, including those who are refractory to standard treatments. This positive outcome is particularly notable in late-line populations where survival rates are typically lower.
Additionally, Agenus’s strategic partnership with Zydus is expected to provide substantial financial support, facilitating the initiation of the Phase 3 BATTMAN trial. The recent authorization for compassionate use of their treatment in France further underscores the potential for regulatory approval in broader markets. These factors collectively contribute to a favorable outlook for Agenus, justifying the Buy rating.
According to TipRanks, Bodnar is a 4-star analyst with an average return of 5.9% and a 37.02% success rate. Bodnar covers the Healthcare sector, focusing on stocks such as Agenus, Olema Pharmaceuticals, and Atossa Therapeutics.